<DOC>
	<DOCNO>NCT00238251</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Gefitinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together either gefitinib temozolomide may kill tumor cell . PURPOSE : This randomized phase II trial study well give radiation therapy together either gefitinib temozolomide work treat patient non-small cell lung cancer brain metastasis .</brief_summary>
	<brief_title>Radiation Therapy Combined With Either Gefitinib Temozolomide Pats With NSCLC Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy whole-brain radiotherapy combine either gefitinib temozolomide , term overall survival , patient non-small cell lung cancer brain metastasis . Secondary - Compare tolerability toxicity regimens patient . - Compare time neurological disease progression , time extracranial disease progression , time overall disease progression , patient treat regimen . - Compare adverse event patient treat regimen . - Compare cognitive function quality life patient treat regimen . OUTLINE : This randomize , open-label , parallel-group , multicenter study . Patients stratify accord extracranial disease ( yes v ) , number brain metastasis ( 1-3 v ≥ 4 ) , prior chemotherapy ( yes v ) , WHO performance status ( 0-1 v 2 ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo whole-brain radiotherapy ( WBRT ) daily day 1-5 8-12 receive oral gefitinib daily day 1-28 . Gefitinib treatment repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients undergo WBRT arm I receive oral temozolomide daily day 1-21 . Temozolomide treatment repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess baseline day 1 course 2 , 3 , 5 . After completion study therapy , patient follow every 3 month . PROJECTED ACCRUAL : A total 30-86 patient ( 15-43 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer AND newly diagnose brain metastasis meet 1 follow criterion : Multiple brain metastasis Single brain metastasis amenable potentially curative treatment No advance extracranial disease severely compromise vital function performance PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Hemoglobin &gt; 10 g/dL Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN ( 5 time ULN presence document bone metastasis ) No unstable uncompensated hepatic disease would preclude study participation Renal Creatinine clearance ≥ 40 mL/min No unstable uncompensated renal disease would preclude study participation Cardiovascular No myocardial infarction within past 3 month No unstable uncompensated cardiac disease would preclude study participation Pulmonary No clinically active interstitial lung disease Patients chronic stable radiographic change asymptomatic eligible No unstable uncompensated respiratory disease would preclude study participation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment No nausea , vomit , inability swallow whole tablets/capsules , malabsorption syndrome would preclude oral medication ingestion absorption No psychiatric disorder would preclude give informed consent study compliance No active infection No uncontrolled diabetes mellitus No medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior temozolomide Endocrine therapy Concurrent corticosteroid allow provide dose stable decrease ≥ 4 day study entry Radiotherapy No prior brain irradiation Surgery Not specify Other No prior gefitinib erlotinib More 30 day since prior investigational clinical trial participation No concurrent experimental drug No concurrent anticancer therapy No concurrent treatment follow : Phenytoin Carbamazepine Rifampin Barbiturates Hypericum perforatum ( St. John 's wort ) Other enzymeinducing antiepileptic drug tuberculostatic treatment Any drug contraindicates administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>